Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778206 · ClinicalTrials.gov registry record
PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 1,887
- Enrollment target
NCT00778206: Completed study, sponsored by BioMarin Pharmaceutical.
NCT00778206 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 1,887 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778206 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 1,887 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety of long-term treatment with Kuvan.
Primary Outcome
Registry data including demographic and baseline characteristics
Interventions
- DRUG Kuvan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,887 participants |
| Start Date | 2008-09 |
| Est. Completion | 2021-01-29 |
What the finished NCT00778206 record still lists
NCT00778206 is an observational study that tracks outcomes without assigning an intervention. Its 1,887 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Kuvan is the first listed.
NCT00778206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00778206 about?
NCT00778206 is a clinical study titled "PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry". The objective of this study is to evaluate the safety of long-term treatment with Kuvan.
What is the current status of trial NCT00778206?
This trial is currently completed. The enrollment target is 1,887 participants. The study started on 2008-09. Estimated completion is 2021-01-29.
What interventions are being tested in trial NCT00778206?
The interventions under investigation include: Kuvan (DRUG).
Who is sponsoring clinical trial NCT00778206?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
- NCT07308717 · 1,896 participants · Phase 4
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia